Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652038 | 1.00 | HCAR3 (0.44) | HCAR3KDM4EGLAS100A4TRPV1 | |
| SCHEMBL16654154 | 0.84 | HCAR3 (0.38) | HCAR3KDM4EGLAS100A4TRPV1 | |
| SCHEMBL17556134 | 0.83 | KIF18A (0.46) | HCAR3MAPK1MAPTSMN1; SMN2LMNA | |
| SCHEMBL28799519 | 0.83 | HCAR3 (0.44) | HCAR3KDM4EGLAMEN1KMT2A | |
| SCHEMBL17556135 | 0.83 | KIF18A (0.46) | HCAR3MAPK1MAPTSMN1; SMN2LMNA | |
| SCHEMBL1648161 | 0.80 | PTGDR2 (0.36) | KDM4EGLAMEN1KMT2AMAPT | |
| SCHEMBL248343 | 0.79 | NPSR1 (0.44) | KDM4EMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL248344 | 0.79 | NPSR1 (0.44) | KDM4EMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL26911664 | 0.78 | MAPT (0.41) | HCAR3MEN1KMT2AMAPK1MAPT | |
| SCHEMBL2191688 | 0.77 | RAB9A (0.37) | KDM4EGLAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278823-B | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | ADVNET PHARMA CO. LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| CN-111278823-A | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | HCAR3 1169/4885KDM4E 399/4885GLA 2974/4885 |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR4, FGFR2 | HCAR3 622/4885KDM4E 703/4885GLA 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.